Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry consortium.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 10 2022
Historique:
revised: 02 05 2022
received: 02 03 2022
accepted: 04 05 2022
pubmed: 29 5 2022
medline: 27 8 2022
entrez: 28 5 2022
Statut: ppublish

Résumé

Black women diagnosed with epithelial ovarian cancer have poorer survival compared to white women. Factors that contribute to this disparity, aside from socioeconomic status and guideline-adherent treatment, have not yet been clearly identified. We examined data from the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium which harmonized data on 1074 Black women and 3263 white women with ovarian cancer from seven US studies. We selected potential mediators and confounders by examining associations between each variable with race and survival. We then conducted a sequential mediation analysis using an imputation method to estimate total, direct, and indirect effects of race on ovarian cancer survival. Black women had worse survival than white women (HR = 1.30; 95% CI 1.16-1.47) during study follow-up; 67.9% of Black women and 69.8% of white women died. In our final model, mediators of this disparity include college education, nulliparity, smoking status, body mass index, diabetes, diabetes/race interaction, postmenopausal hormone (PMH) therapy duration, PMH duration/race interaction, PMH duration/age interaction, histotype, and stage. These mediators explained 48.8% (SE = 12.1%) of the overall disparity; histotype/stage and PMH duration accounted for the largest fraction. In summary, nearly half of the disparity in ovarian cancer survival between Black and white women in the OCWAA consortium is explained by education, lifestyle factors, diabetes, PMH use, and tumor characteristics. Our findings suggest that several potentially modifiable factors play a role. Further research to uncover additional mediators, incorporate data on social determinants of health, and identify potential avenues of intervention to reduce this disparity is urgently needed.

Identifiants

pubmed: 35633315
doi: 10.1002/ijc.34141
pmc: PMC9420829
mid: NIHMS1811597
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1228-1239

Subventions

Organisme : NCI NIH HHS
ID : K01 CA212056
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA173642
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058598
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058420
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164974
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA076016
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207260
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA142081
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164974
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States

Informations de copyright

© 2022 UICC.

Références

CA Cancer J Clin. 2020 Jan;70(1):31-46
pubmed: 31661164
Epidemiology. 2010 Jul;21(4):540-51
pubmed: 20479643
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
Cancer. 2017 Dec 15;123 Suppl 24:5138-5159
pubmed: 29205312
Int J Cancer. 2006 Dec 15;119(12):2907-15
pubmed: 16998830
Am J Epidemiol. 2000 Feb 15;151(4):346-57
pubmed: 10695593
J Clin Oncol. 2021 Jun 20;39(18):2037-2048
pubmed: 33939491
Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1511-1518
pubmed: 28751475
Int J Cancer. 2009 Mar 15;124(6):1409-15
pubmed: 19065661
JNCI Cancer Spectr. 2019 Oct 09;3(4):pkz084
pubmed: 31840133
Am J Epidemiol. 2012 Aug 1;176(3):190-5
pubmed: 22781427
BMC Cancer. 2014 Sep 22;14:688
pubmed: 25242549
Environ Res. 2017 Jul;156:388-393
pubmed: 28395243
Cancer Causes Control. 2019 Sep;30(9):967-978
pubmed: 31236792
Epidemiol Methods. 2014 Jan;2(1):95-115
pubmed: 25580377
Soc Sci Med. 2010 Jul;71(2):274-281
pubmed: 20483517
J Clin Oncol. 2017 Jun 1;35(16):1829-1835
pubmed: 28388292
Ann Epidemiol. 2015 Aug;25(8):556-63
pubmed: 25986734
JACC Heart Fail. 2020 Jan;8(1):57-66
pubmed: 31676303
Ann Epidemiol. 2003 Oct;13(9 Suppl):S18-77
pubmed: 14575939
Cancer Epidemiol. 2019 Feb;58:77-82
pubmed: 30528360
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Br J Cancer. 2015 Sep 1;113(5):817-26
pubmed: 26151456
Epidemiol Health. 2017 Aug 6;39:e2017035
pubmed: 29121709
Cancer Prev Res (Phila). 2012 Jul;5(7):901-10
pubmed: 22609763
Epidemiology. 2014 Mar;25(2):300-6
pubmed: 24487213
Stat Med. 2009 Jul 10;28(15):1982-98
pubmed: 19452569
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9
pubmed: 21499542
Obstet Gynecol. 2012 Jan;119(1):68-77
pubmed: 22183213
Br J Cancer. 2016 Nov 22;115(11):1391-1399
pubmed: 27701384
Int J Epidemiol. 2014 Oct;43(5):1656-61
pubmed: 24860122
Clin Cancer Res. 2016 Dec 1;22(23):5909-5914
pubmed: 27521449
Stat Med. 2018 Jun 30;37(14):2252-2266
pubmed: 29682776
Am J Epidemiol. 2017 Jul 15;186(2):184-193
pubmed: 28472328
Int J Cancer. 2017 Jun 1;140(11):2422-2435
pubmed: 28063166
Gynecol Oncol. 2011 May 1;121(2):364-8
pubmed: 21288564
Cancer Causes Control. 2017 May;28(5):385-391
pubmed: 28025764
Cancer Causes Control. 2014 May;25(5):633-7
pubmed: 24532025
Cancer Epidemiol. 2015 Jun;39(3):353-9
pubmed: 25841586
Health Equity. 2021 Feb 25;5(1):49-58
pubmed: 33681689
Epidemiology. 2006 Jan;17(1):104-7
pubmed: 16357602
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):539-545
pubmed: 30487136
Stat Med. 2019 Feb 10;38(3):398-412
pubmed: 30255567
Gynecol Oncol. 2021 Jan;160(1):10-15
pubmed: 33208254
J Clin Oncol. 2015 Dec 10;33(35):4138-44
pubmed: 26417001
Am J Public Health. 2003 Jul;93(7):1137-43
pubmed: 12835199
Adv Cancer Res. 2020;146:1-21
pubmed: 32241384
Br J Cancer. 2017 Mar 28;116(7):964-971
pubmed: 28208158
J Pain. 2012 Feb;13(2):176-86
pubmed: 22248982
Br J Cancer. 2009 Jun 2;100(11):1806-11
pubmed: 19401693

Auteurs

Holly R Harris (HR)

Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.

Kristin A Guertin (KA)

Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Tareq F Camacho (TF)

Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.

Courtney E Johnson (CE)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Anna H Wu (AH)

University of Southern California Norris Comprehensive Cancer Center and Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California, USA.

Patricia G Moorman (PG)

Department of Family Medicine and Community Health, Duke University Medical Center, Durham, North Carolina, USA.

Evan Myers (E)

Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA.

Traci N Bethea (TN)

Office of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Campus, Washington, District of Columbia, USA.

Elisa V Bandera (EV)

Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.

Charlotte E Joslin (CE)

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago School of Medicine and Division of Epidemiology and Biostatistics, School of Public Health, Chicago, Illinois, USA.

Heather M Ochs-Balcom (HM)

Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, New York, USA.

Lauren C Peres (LC)

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

Will T Rosenow (WT)

Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.

Veronica W Setiawan (VW)

University of Southern California Norris Comprehensive Cancer Center and Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California, USA.

Alicia Beeghly-Fadiel (A)

Department of Medicine, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Lauren F Dempsey (LF)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Lynn Rosenberg (L)

Slone Epidemiology Center at Boston University, Boston, Massachusetts, USA.

Joellen M Schildkraut (JM)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH